balanced crystalloid

ApprovedSmall molecule

SSeoul National University Hospital

balanced crystalloid is one of 152 small molecule programs targeting Acute Pancreatitis. It is currently in Approved.

Indications

Total Trials

Active Trials

151

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute PancreatitisActive, not recruiting

Brain InjuryActive, not recruiting

SepsisActive, not recruiting

Septic ShockActive, not recruiting

Acute Kidney InjuryActive, not recruiting

Acute PancreatitisApproved

Active, not recruiting

Brain InjuryPhase 3

Active, not recruiting

SepsisPhase 3

Active, not recruiting

Septic ShockPreclinical

Active, not recruiting

Acute Kidney InjuryPreclinical

Active, not recruiting

Competition

Competitive Landscape

308 competitors in Sepsis

#DrugCompanyPhaseTrials

balanced crystalloid

SSeoul National University Hospital

Approved

1 2

Corlanor

Amgen

Preclinical

2 3

Simdax

Orion Corporation, Orion Pharma

Preclinical

1 4

Zyvox

Zemplar

Brevibloc

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

3 7

Epsom Salt

FFresenius Kabi Oncology Ltd.

Preclinical

1 8

Aquasol a

BBandim Health Project

Preclinical

1 9

Micardis

Boehringer Ingelheim

Preclinical

1 10

Levaquin

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Post-ApprovalNot yet recruiting

Acute Kidney Injury

NCT07464431

Q3 2029

Phase 3Recruiting

Brain Injury

NCT06953674

Clinical

Trials by Indication[1]

Acute Kidney Injury2 trials

Intraoperative Normal Saline Administration and Acute Kidney Injury in Patients Undergoing Liver Transplantation

Unknown status·SSeoul National University Hospital··NCT05386953·1,440 enrolled

Evaluating the Clinical Effectiveness of Sodium Bicarbonate for Critically Ill Patients With Metabolic Acidosis and Acute Kidney Injury

Not yet recruiting·UUniversität Münster·Phase 4·NCT07464431·660 enrolled

Brain Injury1 trial

Saline Versus Balanced Crystalloid in Traumatic Brain Injury

Recruiting·UUniversity of Louisville·Phase 3·NCT06953674·600 enrolled

Sepsis1 trial

Feasibility of 5% Albumin Compared With Balanced Crystalloid, as Intravenous Fluid Resuscitation in Adult Patients With Sepsis, Presenting as an Emergency to Hospital

Completed·UUniversity of Edinburgh·Phase 3·NCT04540094·300 enrolled

Hemorrhagic Shock1 trial

Initial Resuscitation With Albumin in Hemorrhagic Shock to Reduce Positive Fluid Balance

Unknown status·SSeoul National University Hospital·N/A·NCT06111261·36 enrolled

Acute Pancreatitis1 trial

Balanced Crystalloid Solutions for Acute Pancreatitis

Unknown status·UUniversity Hospital Rijeka·Phase 4·NCT04688645·276 enrolled

4 more indications

Septic Shock1 trial

Balanced Crystalloid vs. Saline in Children With Septic Shock

Completed·—·N/A·NCT02835157·708 enrolled

Fluid Therapy1 trial

Fluid Therapy During Brain Tumor Resection in Children

Completed·FFederal University of São Paulo·Phase 2·NCT02707549·53 enrolled

Intraoperative1 trial

Metabolomics of Intraoperative Saline and Balanced Crystalloid Infusion

Completed·NNational Taiwan University Hospital·N/A·NCT04137042·56 enrolled

Colorectal Surgery1 trial

Perioperative Colloid vs Crystalloid in Patients Undergoing Colorectal Surgery

Terminated·UUniversity Hospital Muenster·Phase 4·NCT01303250·31 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for balanced crystalloid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — balanced crystalloid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for balanced crystalloid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Seoul National University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: SSeoul National University Hospital

balanced crystalloid

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q3 2029

Trials by Indication[1]

Acute Kidney Injury2 trials

Brain Injury1 trial

Sepsis1 trial

Hemorrhagic Shock1 trial

Acute Pancreatitis1 trial

Septic Shock1 trial

Fluid Therapy1 trial

Intraoperative1 trial

Colorectal Surgery1 trial

References

Drug Info

Quick Facts

Related News